China's clinical exemption catalogue isn't a blank pass

This blog has already covered how Brazil's ANVISA structures its own device registration, and how Korea's MFDS sorts a review by who does it, not just how much of it happens. China's National Medical Products Administration publishes something that sounds, from its own name, like the cleanest way out of clinical evidence a manufacturer could ask for: a catalogue of device types exempt from clinical evaluation. The name is accurate as far as it goes, and it goes less far than it sounds — qualifying for the catalogue doesn't mean a file skips evidence. It means the file argues a different case, against a comparator NMPA already named.

Registration is sorted by class before any exemption applies

NMPA's Regulations on the Supervision and Administration of Medical Devices — State Council Order No. 739, effective 1 June 2021 — classify devices into three tiers and route each to a different authority. Class I devices go through a filing: at the municipal-level drug regulatory department for a domestic manufacturer, or directly with NMPA for an imported device. Class II devices register with the provincial-level Medical Products Administration. Class III devices register with NMPA itself. A foreign manufacturer with no China-based entity also has to designate a China-based Agent before filing anything, and that role carries duties beyond submitting paperwork: helping the registrant maintain a quality management system appropriate to the product, running post-market adverse-event monitoring, and executing product traceability and recall if either becomes necessary. The clinical exemption catalogue sits downstream of all of this — it changes what evidence a Class II or III file has to carry, not which authority reviews it or who is standing behind it in China.

Qualifying for the list is a statutory test, not a category match

A device type reaches the catalogue — 免于临床评价医疗器械目录, the Catalogue of Medical Devices Exempt from Clinical Evaluation, maintained and periodically updated by NMPA's Center for Medical Device Evaluation — by meeting one of three conditions: the device's working mechanism is clear and its design and production process are mature, with years of marketed use and no serious adverse-event history and no change in its conventional use; or its safety and effectiveness can be confirmed through non-clinical evaluation alone; or existing clinical trial or clinical-use data on the same type of device is sufficient to confirm it. None of the three conditions is “this device resembles something else on the list.” A device has to fit the reasoning the catalogue entry was built on, not merely share a product category with it.

What the exemption actually removes is the trial, not the dossier

A manufacturer whose device type appears on the catalogue still has to submit a comparison dossier — matching the device against the catalogue's own written description of that device type, and separately against a specific, already NMPA-approved domestic device named as the comparator. That comparison is the evidence the catalogue substitutes for a clinical trial, not a substitute for evidence altogether. A device that can't be matched cleanly against both the catalogue description and a real comparator doesn't get the exemption on the strength of being the same general kind of product; it falls back to the clinical evaluation route the catalogue exists to let some devices skip, which for a novel or higher-risk device can mean a clinical trial run inside China rather than data gathered anywhere else.

The registration that results still runs on its own clock

Whichever route produced it, an NMPA registration is valid for five years, and a renewal application has to be filed no later than six months before it expires; if the authority hasn't acted by the expiry date, the existing registration continues until it does. That renewal clock runs independently of the clinical-exemption question — a device that qualified for the catalogue at first registration doesn't get re-tested against the catalogue at renewal, but a file that tracks only the original exemption basis, with no separate row for when the five-year registration itself comes due, is tracking half the schedule the device is actually on.

Where this meets the file

A China registration tracker needs the exemption basis recorded as its own field — which of the three statutory conditions applied, and which specific comparator device the comparison dossier was built against — kept separate from the registration's own five-year renewal date, so a device doesn't get treated as evidence-exempt on a question the catalogue was never asked to answer. A cross-border registration tracker built to carry that structure, alongside the launch catalog's other device-registration templates, is previewed there now. If your program has run a device through this catalogue and found a gap this one misses, the shelf takes that correction directly.